Company intelligence / Profile preview
TearSolutions, Inc.
Charlottesville, Virginia, United Statestearsolutions.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase I/II clinical trial of Lacripep in primary Sjögren's Syndrome patients, showing statistically significant improvement in both sign (inferior corneal staining) and symptom (burning and stinging) at two weeks[5]. Currently preparing for Phase II clinical trial to evaluate safety and efficacy in the general DED population[5].
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- Peptide therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on TearSolutions, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TearSolutions, Inc..